Targeted protein degradation pushes cancer therapy toward historically untouchable drivers
Targeted protein degradation has moved from an experimental concept to a practical strategy in oncology, and its appeal is easy to see. Instead of trying to block a protein’s function at one active site, the approach removes the protein altogether by co-opting the cell’s own disposal machinery. In cancer, that matters most for targets that have long resisted conventional small-molecule inhibition, including transcription factors, chromatin remodelers, and proteins that act through protein-protein interactions rather than enzymatic activity.
The therapeutic logic is direct. If a malignant cell depends on a pathogenic protein to maintain proliferation, survival, or transcriptional control, then eliminating the protein can be more decisive than simply inhibiting it. Endogenous degradation systems such as the ubiquitin-proteasome pathway and lysosomal pathways provide the biologic machinery for that elimination. This makes TPD fundamentally different from classical inhibition, and it is why the field has drawn intense interest across cancer drug development.
One degradation-based agent, vepdegestrant, has reached FDA approval. Most other agents remain in Phase I or II evaluation. That split captures the current state of the field: clinical translation has begun, but the pipeline is still early, and broad routine use has not yet arrived.
Why undruggable cancer proteins became the central problem
Cancer drug development has repeatedly run into the same wall: many of the most biologically important oncogenic drivers do not offer an easy binding pocket, catalytic site, or conventional pharmacologic handle. Transcription factors illustrate the problem well. They often regulate gene expression through large, dynamic interfaces rather than a discrete enzyme active site, making classic inhibitor design difficult. Chromatin remodelers create a similar challenge because they operate through complex macromolecular assemblies. Proteins mediating protein-protein interactions can be equally difficult to suppress with traditional agents.
TPD turns that problem on its head. Rather than asking whether a target can be inhibited, it asks whether the target can be physically eliminated from the cell. Once the protein is removed, its downstream signaling and transcriptional effects can collapse more completely than they would under partial inhibition. In a disease driven by adaptive signaling and redundant escape pathways, that difference is not trivial.
The review separates these proteins into three categories. Structurally undruggable targets remain the most difficult, because they lack the features that conventional medicinal chemistry usually exploits. A second group includes targets that were once considered undruggable but are now accessible to inhibitors, where degradation may still offer a mechanistic edge. The third group consists of non-enzymatic targets, which are often essential to cancer biology yet remain poor candidates for standard inhibition.
The biology of removal is more powerful than blockade
TPD succeeds because the cell already knows how to destroy proteins. The ubiquitin-proteasome system tags proteins for degradation, while lysosomal pathways can clear additional classes of cellular cargo. TPD strategies harness those routes to force selective protein loss. In practical terms, that can create a deeper and more durable biologic effect than transient occupancy by an inhibitor.
For oncology, the bedside implication is straightforward. A target protein that is difficult to suppress pharmacologically may still be highly vulnerable if it can be routed into a degradation pathway. This is especially relevant for oncogenic proteins that lack enzymatic activity but remain central to tumor maintenance. Removing such proteins can disrupt transcriptional programs, epigenetic regulation, and signaling complexes in a way that standard inhibition may not fully achieve.
A durable antitumor effect depends on more than binding affinity. It depends on whether the drug can induce sustained loss of the disease-driving protein inside the cell.
Clinical translation is real, but still early
The approval of vepdegestrant marks a genuine regulatory milestone for the field. Even so, the current development landscape remains dominated by early-phase studies. Most agents are still in Phase I or II, which means the field has not yet reached the point where broad comparative efficacy, long-term safety, or resistance patterns are well defined across large populations.
That early-stage reality should not be mistaken for lack of momentum. It reflects how quickly the science has advanced from concept to clinic. The review frames TPD as a platform with the potential to address previously intractable cancer targets, but also makes clear that many disease-relevant proteins remain difficult to modulate effectively. Some targets may resist degradation entirely. Others may prove accessible only in specific tumor contexts or through particular delivery designs.
The field’s biggest strength is also its greatest challenge: TPD is not a single drug class but a strategy that must be matched to target biology. A protein’s structure, cellular localization, turnover, and role in oncogenic signaling all influence whether degradation will work.
Three target classes define where the field can expand next
The review’s three-category framework is clinically useful because it separates what is possible now from what remains aspirational. Structurally undruggable targets represent the most obvious application for TPD, since they are precisely the proteins most likely to evade standard inhibitor design. Formerly undruggable targets that are now inhibitor-accessible raise a different question: if a drug can inhibit the target, does degradation still offer enough added value to justify the complexity of the approach? In some settings, it may.
Non-enzymatic targets may become one of the most important testing grounds for the technology. These proteins often matter deeply in cancer biology but have no catalytic function to inhibit. Degradation offers a direct way to remove their contribution to malignant behavior. That is a biologically elegant solution to a problem medicinal chemistry has struggled with for decades.
Still, elegance does not guarantee success. The review closes with the recognition that a substantial number of important proteins remain hard to modulate effectively, even with current TPD tools. That is the central tension in the field: the method has already delivered a first approval and a growing trial portfolio, yet the set of truly tractable targets is still narrower than the full list of cancer drivers.
What the 2026 cutoff means for oncology drug development
By setting a cutoff of 30 September 2026, the review captures a field moving quickly enough that the evidence base is already shifting underneath it. That matters for interpretation. Drug development in TPD is progressing, but the available clinical data are still early and incomplete, and the next phase will determine which target classes can support durable, safe, and scalable therapy.
For oncologists and translational researchers, the immediate implication is not that TPD has solved the undruggable target problem. It has not. The more precise conclusion is that the problem is now being attacked with a tool that directly addresses protein presence rather than protein function. In cancers driven by elusive transcriptional regulators, chromatin proteins, and other non-enzymatic machinery, that may be the difference between theoretical interest and therapeutic relevance.
The unanswered issues are practical: which targets degrade reliably, which tumor types respond, and which agents can move beyond early-phase study into routine clinical use. Those questions will determine whether targeted protein degradation remains a specialized strategy or becomes a broader pillar of cancer therapeutics.